Showing 2291-2300 of 20882 results for "".
- FDA Accelerated Approval of Atrasentan: A New Era for IgA Nephropathy Treatmenthttps://reachmd.com/news/fda-accelerated-approval-of-atrasentan-a-new-era-for-iga-nephropathy-treatment/2475057/Atrasentan’s FDA accelerated approval introduces a novel non-steroidal option for patients with IgA nephropathy facing limited effective treatments. The clinical management of IgA nephropathy has long been constrained by reliance on co
- Bridging the Gap: Reinvigorating Interest in Pain Medicine Fellowshipshttps://reachmd.com/news/bridging-the-gap-reinvigorating-interest-in-pain-medicine-fellowships/2475052/Program directors are confronted with a pivotal challenge as anesthesia residents increasingly bypass pain medicine fellowship training</
- Unmasking IL-17: A New Frontier in Spondyloarthritis Managementhttps://reachmd.com/news/unmasking-il-17-a-new-frontier-in-spondyloarthritis-management/2475050/A growing body of evidence reveals that IL-17-driven inflammation in spondyloarthritis remains underrecognized, even as it shapes disease activity and treatment response. Persistent inflammation poses a significant challenge in spondyl
- Innovative Approaches to Combat Antimicrobial Resistance in Gram-Positive Pathogenshttps://reachmd.com/news/innovative-approaches-to-combat-antimicrobial-resistance-in-gram-positive-pathogens/2474991/The rise in antimicrobial resistance necessitates innovative treatment approaches for resistant gram-positive pathogens. Infectious disease specialists confronting persistent cases of drug-resistant gram-positive pathogens, including m
- Enhancing Preterm Infant Nutrition: Emerging Insights into Maternal Diet and Milk Compositionhttps://reachmd.com/news/enhancing-preterm-infant-nutrition-emerging-insights-into-maternal-diet-and-milk-composition/2475027/Optimizing preterm infant nutrition through targeted maternal diet represents a pivotal yet underutilized strategy to enhance the nutrient density of human milk, addressing the unique vulnerabilities of preterm infants. Neonatologists
- Emerging Integrations in Cardiovascular Risk: The Role of Inflammatory and Metabolic Indiceshttps://reachmd.com/news/emerging-integrations-in-cardiovascular-risk-the-role-of-inflammatory-and-metabolic-indices/2475037/As the burden of metabolic syndrome rises, clinicians are recognizing that systemic inflammatory and metabolic markers are not mere bystanders but powerful predictors of cardiovascular outcomes, demanding a reevaluation of risk stratification
- Redefining Coronary Artery Disease Intervention: Novel Approaches in Pharmacology, Surgery, and Imaginghttps://reachmd.com/news/redefining-coronary-artery-disease-intervention-novel-approaches-in-pharmacology-surgery-and-imaging/2475034/Clinicians have long grappled with the narrow therapeutic window of antiplatelet therapy in coronary artery disease, where the protection against thrombosis with aspirin comes at the cost of residual ischemic events and potent alternatives ra
- Bridging Subclinical Rheumatoid Arthritis and Gut Health for Early Interventionhttps://reachmd.com/news/bridging-subclinical-rheumatoid-arthritis-and-gut-health-for-early-intervention/2475029/Rheumatoid arthritis often evades timely diagnosis due to its varied and often unpredictable symptoms, prompting a new focus on pre-clinical screening and the gut-immune axis as avenues for early intervention. The identification of pre
- Integrating Translational Science Breakthroughs in Alzheimer's Carehttps://reachmd.com/news/integrating-translational-science-breakthroughs-in-alzheimers-care/2475028/Clinicians face a narrowing window to integrate translational science breakthroughs and biomarker innovations that are reshaping Alzheimer's care, from the earliest diagnostic intervals to emerging targeted therapies. Current diagnosti
- Exploring Advancements in Interleukin-2 Formulations and Their Potential in Dermatologyhttps://reachmd.com/news/exploring-advancements-in-interleukin-2-formulations-and-their-potential-in-dermatology/2475026/Clinicians have long grappled with multiple challenges, including systemic toxicities, dosing complexities, and formulation instability, that limited the therapeutic use of IL-2 in skin disorders, but a recent U.S. patent grant for